Generate Biomedicines, a Flagship Pioneering-founded antibody platform company, has filed for an initial public offering as part of a growing wave of biotech listings in early 2026. The company has not disclosed the size or price range of the offering but outlined in its SEC filing that funds will be directed primarily toward advancing its lead AI-designed asthma program, GB-0895.
Founded in 2018 under the leadership of Merck & Co. veteran Mike Nally, Generate has secured major strategic deals…
